CELL INTELLIGENCE · 肿瘤细胞治疗研究

SPP1 阳性巨噬细胞驱动 HER2 阳性乳腺癌曲妥珠单抗耐药

SPP1-positive macrophages drive trastuzumab resistance in HER2-positive breast cancer.

靶向 PD-L1 和 ErbB2（HER2）的双重 CAR-NK 细胞表现出协同 CAR 信号传导并抵抗实体瘤异质性

Dual CAR-NK cells targeting PD-L1 and ErbB2 (HER2) exhibit cooperative CAR signaling and counteract solid tumor heterogeneity.

同时靶向 PD-L1 与 ErbB2 可通过对抗原异质性提供抵抗力并经协同激活放大抗肿瘤信号，增强 CAR-NK 细胞对难治性实体瘤的疗效。

一种肿瘤靶向七甲川花菁染料通过诱导致死性自噬抑制三阴性乳腺癌

A tumor-targeted heptamethine cyanine dye suppresses triple-negative breast cancer by induction of lethal autophagy.

本研究介绍了一种可能有效增强 TNBC 治疗效果的策略。

差异 FGFR1 拷贝数状态在三阴性乳腺癌中展示独特的肿瘤免疫微环境

Differential FGFR1 copy number status displays unique tumour immune microenvironment in triple-negative breast cancer.

解码三阴性乳腺癌的肿瘤微环境：从免疫逃逸到精准免疫治疗

Decoding the tumor microenvironment of triple-negative breast cancer: from immune evasion to precision immunotherapy.

铂类激活 NK 细胞增强 HR(+)/HER2(-) 乳腺癌免疫治疗

NK Cell Activation by Platinum Boosts Immunotherapy in HR(+)/HER2(-) Breast Cancer.

用于调节三阴性乳腺癌免疫微环境的纳米药物递送系统的最新进展

Latest advances in nanodrug delivery systems for modulating the immune microenvironment in triple-negative breast cancer.

一种 Fc 工程化糖修饰抗体支持免疫效应细胞的促炎激活并限制乳腺癌进展

An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer.

利用脐血 CD34⁺ HSPC 来源的间皮素特异性 CAR-NKT 细胞靶向三阴性乳腺癌，具有强效抗肿瘤活性

Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity.

这些结果支持 Allo15 MCAR-NKT 细胞作为一种下一代、现成的免疫疗法，对 TNBC 具有强大的治疗潜力，特别是在转移、免疫逃逸和治疗耐药的情况下。

靶向 ErbB2/HER2 的 CAR-NK 细胞在重现肿瘤进展的类器官模型中清除乳腺癌细胞

ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression.